Cargando…

Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

Detalles Bibliográficos
Autores principales:	Morrell, Liz, Wordsworth, Sarah, Schuh, Anna, Middleton, Mark R., Rees, Sian, Barker, Richard W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437939/ https://www.ncbi.nlm.nih.gov/pubmed/30922313 http://dx.doi.org/10.1186/s12913-019-4039-8

Ejemplares similares

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals
por: Morrell, Liz, et al.
Publicado: (2018)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
por: Morrell, Liz, et al.
Publicado: (2017)

EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties
por: Dickson, Rumona, et al.
Publicado: (2018)

Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics
por: Morrell, Liz, et al.
Publicado: (2017)

Cancer as the “perfect storm”? A qualitative study of public attitudes to health conditions
por: Morrell, Liz, et al.
Publicado: (2017)

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias
por: Brown, Patrick, et al.
Publicado: (2011)

What Aspects of Illness Influence Public Preferences for Healthcare Priority Setting? A Discrete Choice Experiment in the UK
por: Morrell, Liz, et al.
Publicado: (2021)

The impact of rarity in NICE’s health technology appraisals
por: Clarke, Sophie, et al.
Publicado: (2021)

Reply 2: NICE guidelines on drugs for colorectal cancer
por: Ross, P J, et al.
Publicado: (2003)

Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
por: Hashem, Ferhana, et al.
Publicado: (2017)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Flexibility in assessment of rare disease technologies via NICE's single technology appraisal route: a thematic analysis
por: Hale, George, et al.
Publicado: (2023)

Audit of data redaction practices in NICE technology appraisals from 1999 to 2019
por: Osipenko, Leeza
Publicado: (2021)

Determinants of the Cancer Drug Funding Process in Canada
por: Gotfrit, Joanna, et al.
Publicado: (2022)

A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process
por: Kaltenthaler, Eva C, et al.
Publicado: (2012)

It’s not evidence, it’s insight: bringing patients’ perspectives into health technology appraisal at NICE
por: Staley, Kristina, et al.
Publicado: (2016)

Anxiety, depression, and uncertainty appraisal and factors affecting uncertainty risk and opportunity appraisal of health care workers in Korea during the COVID-19 outbreak: Uncertainty risk and opportunity appraisal
por: An, Soo Young, et al.
Publicado: (2023)

Techniques for project appraisal under uncertainty /
por: Reutlinger, Shlomo
Publicado: (1970)

The Role of Funding and Policies on Innovation in Cancer Drug Development
por: Kanavos, P, et al.
Publicado: (2010)

Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2017)

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process
por: Walton, M. J., et al.
Publicado: (2019)

The Challenges of Measuring and Valuing Quality of Life in Preschool Children: A Retrospective Review of NICE Appraisals
por: Lamb, Alan, et al.
Publicado: (2021)

Could NICE guidance on the choice of blood pressure lowering drugs be simplified?
por: Sofat, Reecha, et al.
Publicado: (2012)

Weighty: NICE's Not-So-Nice Words
por: Lozano-Sufrategui, Lorena, et al.
Publicado: (2016)

Professional experiences of accessing cancer drugs in the NHS: the introduction of the Cancer Drugs Fund, the individual versus the population
por: Chamberlain, Charlotte, et al.
Publicado: (2014)

Impact of NIHR HTA Programme funded research on NICE clinical guidelines: a retrospective cohort
por: Turner, Sheila, et al.
Publicado: (2015)

Effects of Uncertainty, Appraisal of Uncertainty, and Self-Efficacy on the Quality of Life of Elderly Patients with Lung Cancer Receiving Chemotherapy: Based on Mishel’s Theory of Uncertainty
por: Hwang, Min-Kyung, et al.
Publicado: (2023)

Have a Nice Conflict: How to Find Success and Satisfaction in the Most Unlikely Places
por: Scudder, Tim, et al.
Publicado: (2011)

Nice
por: Kunkler, Ian
Publicado: (1999)

Simulation contact lenses for AMD health state utility values in NICE appraisals: a different reality
por: Butt, Thomas, et al.
Publicado: (2015)

Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
por: Kaltenthaler, Eva, et al.
Publicado: (2016)

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)

The Most Useful Drugs
Publicado: (1876)

Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform
por: Chen, Yixi, et al.
Publicado: (2016)

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
por: Ramaekers, Bram L. T., et al.
Publicado: (2016)

Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals
por: Rose, Micah, et al.
Publicado: (2017)

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2018)

Childhood Drug and Non-Drug Poisoning in Nigeria: An Economic Appraisal
por: Ikhile, Ifunanya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_uscgpe0qbm9g763mlf5nonhmq5